Medicine Goes to School: Teachers as Sickness Brokers for ADHD
Christine B. Phillips is a Senior Lecturer in Social Foundations of Medicine, Australian National University Medical School, Acton, Australia. E-mail: Christine.phillips@calvary-act.com.au
DOI: 10.1371/journal.pmed.0030182
Copyright: This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abbreviations: ADHD, attention deficit hyperactivity disorder; CHADD, Children and Adults with Attention Deficit/Hyperactivity Disorder
ADHD joins dyslexia and glue ear as disorders that are considered significant primarily because of their effects on educational performance. Medicalising educational performance can help children receive specialised medical and educational services; at the same time it can lead to them receiving medications or surgical therapies which may have short-term and long-term ill effects.
In the case of ADHD, there has been a complex, often heated debate in the public domain about the verity of the illness and the personal cost-benefit ratio of treatment with psychostimulant medication [4–6]. Much of the polemic for and against psychostimulants is concerned with the part played by doctors, the prescribers of medication, in diagnosing or discounting ADHD.
ADHD is, however, a disorder of educational performance, and so teachers have a critical role in advocating for the illness, and its medical treatment. This essay explores the roles of teachers as brokers for ADHD and its treatment, and the strategies used by the pharmaceutical industry to frame educators' responses to ADHD.
The Teacher's Role in Managing ADHD
In his essay on medicalisation processes, Conrad argued that when disorders previously viewed as non-medical are redefined as sicknesses, non-medical people often perform the “everyday routine work” of disseminating understanding of the new sickness [7]. A temperance society worker, for example, might have disseminated the concept of alcoholism as a disease through everyday contacts with alcoholics and their families. With ADHD, the teacher's work extends beyond simply ensuring the disorder is understood by parents. Instead, the teacher participates in the diagnosis, and may broker different forms of treatment, or rejection of treatment. Brokerage is not a disinterested activity: teachers may have a vested interest in detecting and managing disruptive children, or they may adhere to beliefs about learning disorders which lead them to dissuade parents of the need for treatment.The role of the teacher as the sickness and treatment broker for ADHD has been elaborated more clearly for ADHD than for any other childhood disorder. The DSM-IV diagnostic criteria accord teachers a formal role in diagnosis through specialised assessment instruments such as the Conners Teacher's Rating Scale [8]. Teachers often agree to administer psychostimulant medication during the school day, although there is in Australia, the UK, and the US no legal compulsion to do so. A subtle incentive for teachers to administer medication in the middle of the day may be the assurance of a tractable child in the afternoon.
An informal role also exists for teachers as “disease-spotters.” There appears to be considerable difference internationally in the alacrity with which teachers engage in disease-spotting. In a study of 491 physicians in Washington, D. C., almost half of the diagnoses of ADHD in their patients had been suggested first by teachers [9]. In the UK, on the other hand, parental concerns that a child has ADHD may be discounted by teachers [10].
How Drug Companies Influence Teachers
As teachers have some agency in diagnosing ADHD, and may in fact contest the diagnosis, the pharmaceutical industry has an interest in directing teachers toward medical treatment. Pharmaceutical companies have been able to exploit the Internet to access teachers and to influence their brokerage role. The approach to teachers tends to mirror strategies used to familiarise doctors with pharmaceuticals.The pharmaceutical company as disinterested purveyor of education
The drug promotion that masquerades as professional education is such a fixture in the medical domain that many universities train medical students to critique promotional material. Both Shire (manufacturer of Adderell) [11] and Novartis (manufacturer of Ritalin) [12] have established educational websites separate from their own industry sites, each of which contains specific resources for teachers. On a page entitled “If parents ask…,” Novartis suggests responses teachers might make to concerned parents:“Make it clear to them that it is important for them—and their child—to understand and follow the doctor's medical advice about medication and other therapies for ADHD. ADHD is a serious condition that may require the child to be on medication and undergo counselling for a long duration [12].”
Each site incorporates links to the manufacturer responsible for the site [13] or directly to the psychostimulant produced by the manufacturer [14], discussion of the diagnostic process, and references to the legislation governing the rights of access for disabled people to treatment, such as the Individuals with Disabilities Education Act in the US. An activity such as Shire's funding of an annual toll-free “ask the experts” ADHD hotline, 1-888-ASK-ADHD, [15] is another example of the provision of advertorial information to teachers in the guise of objective education. Experts provided for this free hotline, now in its seventh year, include teachers, as well as school nurses, doctors, and advocates; suggested topics include the management of ADHD within the school.
Other school personnel are also targeted. In 1997, Novartis collaborated with the National Association of School Nurses in the US to run a nationwide campaign, in which 11,000 school nurses were provided with a resource kit containing information on ADHD, its treatment, and various support organizations [16]. Novartis later collaborated with the National Association of School Nurses and others to produce a resource aimed at curbing misuse of psychostimulant medication, which again provided links to Novartis pharmaceuticals [17].
Support of advocacy groups which lobby teachers
In the US, the pre-eminent advocacy group for people with ADHD is CHADD (Children and Adults with Attention Deficit/Hyperactivity Disorder). In the 2004–2005 financial year (year ended 30 June 2005), 22% of CHADD's total revenue came from the pharmaceutical industry [16]. CHADD undertakes educational programs for teachers [18], including acting as the lead editorial consultant of a special issue on ADHD in Health in Action, a quarterly publication of the American School Health Association [19]. The UK's answer to CHADD, the National Attention Deficit Disorder Information and Support Service (ADDISS), also carries a brief to develop and publicise educational programs for teachers. A charity-based organisation set up by the Department of Health, the service has also received funding from Janssen-Cilag, UCB Pharma, and Eli Lilley, according to reports in the UK press [20].Creating a presence in the school for the pharmaceutical industry
A more general staking of claim to a role in schools is provided through the range of online science educational materials now provided by GlaxoSmithKline [21], Pfizer [22], and the Association of the British Pharmaceutical Industry [23]. Although these sites do not mention specific medications, they reinforce the place of the pharmaceutical industry as a benevolent and authoritative presence within the school, much as the provision of branded educational materials to doctors reinforces the position of the pharmaceutical industry within the clinic.Conclusion
The organized penetration of the pharmaceutical industry associated with ADHD into the education domain is a new phenomenon. While there has been extensive discussion about the ethics of fast-food marketing within schools [24,25], there has been little about the consequences of the pharmaceutical industry's infiltration of schools.It could be argued that in providing information to teachers, pharmaceutical industries are simply acting as good corporate citizens. Such an argument would carry more weight if these companies also provided education programs addressing autism and dyslexia, two other conditions which impact upon educational performance, but which do not have accepted pharmaceutical therapies. While there is an argument for providing unbiased education to teachers about a high-profile condition, education provided by pharmaceutical companies is self-serving in that it often provides education which references their own products, and channels the reader toward medical therapy.
There are calls for doctors to learn about pharmaceutical marketing strategies in their training [26,27], to participate in the monitoring of outcomes of medication, through post-marketing surveillance, and to maintain a global watch on pharmaceutical marketing [28]. The wide acceptance of disorders of educational performance, and the penetration of the pharmaceutical industry into schools, point to similar needs for teacher training and participation in surveillance (see Box 1). Children have no agency in this market. To be effective advocates for children, teachers need to be supported to be objective and accurate interpreters of information for parents and healthworkers, rather than franchisees in the sickness marketplace. 3
Acknowledgments
I am grateful for comments on this essay from Clare McGuiness and Marjan Kljakovic.References
1. Safer DJ, Zito JM, Fine EM (1996) Increased methylphenidate usage for attention deficit disorder in the 1990s. Pediatrics 98: 1084–1088. Find this article online
2. Miller A, Lee SK, Raina P, Klassen A, Zupanic J et al. (1998) A review of therapies for attention-deficit/hyperactivity disorder. Ottawa: Canadian Coordinating Office for Health Technology Assessment. Available: http://www.ccohta.ca/newweb/pubapp/pdf/adhd_tech_rep.pdf . Accessed 29 January 2006.
3. Salmelainen P (2002) Trends in the prescribing of stimulant medication for the treatment of attention deficit hyperactivity disorder in children and adolescents in New South Wales. N S W Public Health Bull 13(Supplement S-1): 1–65. Find this article online
4. Breggin PR (2002) The Ritalin fact book: What your doctor won't tell you about ADHD and stimulant drugs. Cambridge (Massachusetts): Perseus Publishing. 208 p.
5. Church of Scientology International (2006) Protecting the rights of children. Available: http://www.scientology-europe.org/en_US/pub/human-rights/pg011.html . Accessed 29 January 2006.
6. American Academy of Pediatrics (2006) Children's health topics: ADHD. Available: http://www.aap.org/healthtopics/adhd.cfm . Accessed 29 January 2006.
7. Conrad P (1992) Medicalization and social control. Ann Rev Social 18: 209–232. Find this article online
8. Conners CK (1997) Manual for the Conners' Rating Scales—Revised. North Tonawanda (New York): Multi-Health Systems.
9. Sax L, Kautz KJ (2003) Who first suggests the diagnosis of attention-deficit/hyperactivity disorder? Ann Fam Med 1: 171–174. Find this article online
10. Malacrida C (2004) Medicalization, ambivalence and social control: Mothers' descriptions of educators and ADD/ADHD. Health 8: 61–80.
11. Shire Pharmaceutical Group (2005) ADHD support. Available: http://www.adhdsupportcompany.com . Accessed 23 December 2005.
12. Novartis Pharmaceuticals Corporation (2005) If parents ask…. Available: http://www.adhdinfo.com/info/school/caring/sch_if_parents_ask.jsp . Accessed 19 December 2005.
13. Novartis Pharmaceuticals Corporation (2006) Novartis Pharmaceuticals USA. Available: http://www.pharma.us.novartis.com/index.jsp?TNav . Accessed 14 February 2006.
14. Shire Pharmaceutical Group (2006) Adderell XR. Available: http://www.adderallxr.com . Accessed 14 September 2005.
15. Shire Pharmaceutical Group (2005) Celebrity carpenter Ty Pennington to host ADHD experts on call program [press release]. Available: http://psychcentral.com/news/archives/2005-09/pn-net091405.html . Accessed 14 February 2006.
16. Kidsonline (2006) National Association of School Nurses (NASN) supports educational program about management of attention deficit hyperactivity disorder (ADHD) in schools. Available: http://www.kidsource.com/kidsource/content3/news3/adhd.nurses.html . Accessed 29 January 2006.
17. Novartis Pharmaceuticals Corporation (2002) Straight talk about responsible treatment (START). Available: http://www.adhdinfo.com/startnow/index.jsp . Accessed 29 January 2006.
18. CHADD (2005) CHADD Annual Report 2004–2005. Available: http://www.chadd.org/pdfs/2005_Annual_Report.pdf . Accessed 2005.
19. CHADD (2004) Reaching educators. Available: http://www.chadd.org/webpage.cfm?cat_id=10&subcat_id=77 . Accessed 23 December 2005.
20. Foggo D (2005) ADHD advice secretly paid for by drugs companies. Available: http://www.telegraph.co.uk/news/main.jhtml?xml=/news/2005/10/09/nadhd09.xml . Accessed 29 January 2006.
21. GlaxoSmithKline (2004) Partners with education. Available: http://www.gsk.com/education/index.htm . Accessed 23 December 2005.
22. Pfizer (2004) Pfizer Learning Lab. Available: http://www.pfizerlearninglab.co.uk/hp.aspx . Accessed 23 December 2005.
23. Association of the British Pharmaceutical Industry (2005) Resources for schools. Available: http://www.abpischools.org.uk . Accessed 23 December 2005.
24. Story M, French S (2004) Food Advertising and marketing directed and children and adolescents in the US. Int J Behav Nutr Phys Act 10: 3. Find this article online
25. Linn SE (2004) Food marketing to children in the context of a marketing maelstrom. J Public Health Pol 25: 367–378. Find this article online
26. Rogers WA, Mansfield PR, Braunack-Mayer AJ, Jureidini JN (2004) The ethics of pharmaceutical industry relationships with medical students. Med J Australia 180: 411–414. Find this article online
27. Wilkes MS, Hoffman JR (2001) An innovative approach to educating medical students about pharmaceutical promotion. Acad Med 76: 1271–1277. Find this article online
28. Mansfield PR (1997) MaLAM, a medical lobby for appropriate marketing of pharmaceuticals. Med J Australia 167: 590–592. Find this article online
No comments:
Post a Comment